ArticleInternational journal of molecular sciences2026
Activity and Biocompatibility Evaluation of Enzybiotic Compositions Formulated with
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Due to their availability and environmental friendliness, alginate polymers are widely used in pharmaceuticals and cosmetics. The most common type of alginate is derived from seaweed and is used to develop topical dosage forms, among other things. However, variability in the seaweed material can lead to instability in the physicochemical parameters. Biotechnologically produced alginate minimizes this drawback through controlled synthesis. However, unlike algal alginates, the safety profile of such polymers has not been well studied. When developing dosage forms intended for wound surfaces, safety is of primary importance. In this study, we developed enzybiotic compositions based on bacterial alginate as an excipient and a novel recombinant modified endolysin, LysSi3-LK, as an antibacterial agent, and assessed their antibacterial properties and safety profile. The study included an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.